
CD3-binding (T cell engaging) immune stimulating antibody-based therapies
Learning Objectives
- Understand the pharmacology of T cell engaging molecules and the spectrum of safety liabilities resulting from their mode of action
- Specific challenges for in vivo nonclinical safety studies performed with TCEs i.e. sampling schedules, cytokine release, ADAs, on-target off-tumor toxicity
- Typical nonclinical pharmacology and toxicology package required to support FIH studies and BLA submission
- Current hot topics in the development of TCEs i.e. requirement for 3-month studies, studies required for well-characterized targets, use of surrogate molecules, transgenic animal models
Benno Rattel
Available Credit
- 1.00 Participation